

OHDSI evidence in action

Personalized Oncological Surgery

The right treatment to the right patient at the right time

Klebanov G, MSc², Drakos I, PhD¹, Gögenur I, DMSc¹

¹Center for Surgical Science, Zealand University Hospital, Denmark;

²Odysseus Data Services, Inc, USA.



**Presented by professor Ismail Gögenur, DMSc
Director of the Center for Surgical Science (CSS)**



Center for Surgical Science

leading an international network of excellence for personalized oncological research




- State of the art research and everyday clinical practice based on multidisciplinary collaboration.
- Innovative surgical methods with significant impact on patients' quality of life and treatment cost.
- Incorporating in its organizational structure the main scientific domains of CAG-POS:
 - Surgery
 - Epidemiology
 - Translational Research
 - Big data and personalized surgery
- Participating and leading national, European and international studies about clinical research and development.
 - At CSS we emphasize on **personalized medicine being part of medicine** and has to follow the same GCP as any other medical field and
 - Contribute our expertise in **multidisciplinary collaboration** to ensure the synergy between the different domains involved in personalized oncological research and lead an international network of excellence.





Incidence and mortality rates are increasing



3. most common cancer

- Incidence x 2 in 2030
- Mortality x 2 in 2030

GUT Melina Arnold et al. Gut 2017;66:683-691



Phenotype is essential for prognosis



**More than 1 out 3 patients
dependant / frail**



CRC incidence in younger age groups !



- Increasing incidence < 50 years
- 15% of CRC
- 67% increase from age 40 to 49
- Colon cancer increased 56%
- Rectal cancer increased 94%



More aggressive tumors!


J Am Coll Surg 2011;213(3):352-61 (ISSN: 1879-1190) NCI, SEER Database
Cancer Epidemiol 2016;42:90-100. Prev Med 2017;105:345-9




Evidence is biased!

- 24 cancer drugs approved from 2007-2010

FDA trial populations



Population with cancer



Scher and Hurria JCO 2012



Complications are common after surgery



N = 587 CRC surgery (2015-17)




> 96 % MIS



LOS Colon = 2 days




LOS Rectum = 4 days



10%

Reoperated




13%

Readmitted



14%

LOS > 14 days



25%

Complications


33% of the total hospital budget is used on complications!

Bennedsen et al Col Dis 2018


Goveart et al EJSO 2015



Overtreatment in CRC surgery




Overtreatment?






Cancer recurrence a huge challenge






PERSONALIZED SURGERY





Major recent progress in the understanding and treatment of patients with colorectal cancer needs to be integrated in a **PERSONALIZED** surgical approach.





Immune system in CRC






Galon et al. Science, 2006

Mlechnik et al. Journal of Clinical Oncology, 2011



Immunotherapy has a major potential





Prehabilitation


Prehabilitation

Standard treatment






Stratified approach through risk assessment






Patients like me





High quality and granularity of information leading to improved perioperative patient care?



Eric J. Topol Nat Med 2019




The Project Goal



Creating a platform where both PHENOTYPIC and OMIC data contribute to improve healthcare services.




Research infrastructure





Choosing data sources for the CDM



Colorectal Cancer
Detailed description of all pathology aspects


Pathology
Hospital admissions, procedures and treatments during admission

Medication
Prescriptions and administrations

Biochemistry
27 lab measurements targeting cancer and adverse drug reactions

Anesthesia
Detailed information for colorectal cancer operations


Microbiology
Blood analysis results 180 days after surgery





OHDSI PoC Skills

A wide range of skills and knowledge lead to a tight collaboration





2018 OHDSI PoC

A few known challenges :

- Unfamiliar clinical data with unknown quality and data... What is DCCG? DAD? LPR?
- Danish registry uses Danish medical coding system (SKS), including for diagnosis, procedures, observations - needs custom mappings / vocabularies...
- Multiple data sources (DCCG, BigTempHealth) will be integrated and interlinked...
- 4 - 6 weeks to a completion of the POC
- Highest quality expected


PoC study	Data-source name	Targeted data domain	Variables of interest (approximation)	Number of Records
Colorectal Cancer	Danish Colorectal Cancer Group Database (DCCG)	See table 3 for DCCG data details	350	50.000
Colorectal Cancer	Danish Anaesthesia Database (DAD)	Anaesthesia during CC operations	200	50.000
Colorectal Cancer	Danish National Database of Reimbursed Prescriptions	Anti-diabetic medication and Statins for CC patients	50	50.000
Colorectal Cancer	Danish Civil Registration System	Mortality information for CC patients.	50	50.000
Colorectal Cancer	Danish Pathology Registry (Patobank)	CC recurrence	50	50.000
Colorectal Cancer	Danish Cancer Registry	CC related information	50	50.000
Colorectal Cancer	Danish National Patient Registry	Demographics, diagnosis, treatment, procedure for CC patients	50	50.000
Colorectal Cancer	The Danish Microbiology Database (MiBa)	Microbiology lab values for CC patients	50	50.000
BEFUS	The BEFUS population study	See table 3 for BEFUS data details	350	22.000
BigTempHealth	The BigTempHealth population study	Adverse Drug Reactions	100	200.000

A typical project of this type takes 3-4 calendar months w/ 4-5 FTE resources!!!




CSS OHDSI Tool stack

- ACHILLES database level characterization
- Vocabulary search
- Database level statistics (Achilles)
- Patient profile
- Cohort definitions
- Incidence Rate Analysis tool
- Population-level Estimation (PLE)
- Patient-level Prediction (PLP)
- TxPathways




PoC study	Data-source name	Targeted data domain	Variables of interest (approximation)	Number of Records
Colorectal Cancer	Danish Colorectal Cancer Group Database (DCCG)	See table 3 for DCCG data details	350	50,000
Colorectal Cancer	Danish Anaesthesia Database (DAD)	Anaesthesia during CC operations	200	50,000
Colorectal Cancer	Danish National Database of Reimbursed Prescriptions	Anti-diabetic medication and Statins for CC patients	50	50,000
Colorectal Cancer	Danish Civil Registration System	Mortality information for CC patients.	50	50,000
Colorectal Cancer	Danish Pathology Registry (Patobank)	CC recurrence	50	50,000
Colorectal Cancer	Danish Cancer Registry	CC related information	50	50,000
Colorectal Cancer	Danish National Patient Registry	Demographics, diagnosis, treatment, procedure for CC patients	50	50,000
Colorectal Cancer	The Danish Microbiology Database (MiBa)	Microbiology lab values for CC patients	50	50,000
BEFUS	The BEFUS population study	See table 3 for BEFUS data details	350	22,000
BigTempHealth	The BigTempHealth population study	Adverse Drug Reactions	100	200,000

ETL





OMOP CDM V5.3.1




- ATLAS 2.x only supports OMOP CDM 5.x
- OMOP CDM and vocabularies still have gaps in supporting rich oncology data



OHDSI ATLAS



- Supports complex cohorts building and analytical designs (Characterization, Prediction and Estimation) on OMOP CDM
- Execution of the analytics against local OMOP CDM data
- Installed at most of the OHDSI Network sites




- Enabled PLP/PLE execution from ATLAS with ARACHNE Execution Engine
- OHDSI Team work on making sure ATLAS 2.7.3 is a stable version



OHDSI Achilles (ATLAS Data Sources)

- Provides characterization, quality assessment and visualization of observational health databases.




- Used extensively during testing and for data validation



ATHENA

Allows search, navigation and distribution of the OMOP Standardized Vocabularies



The screenshot shows the ATHENA search interface with the keyword "aspirin" entered. The search results are displayed in a table with columns: ID, CODE, NAME, CLASS, RC, DRC, DOMAIN, and VOCABULARY. The results show multiple entries for "1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution" from various sources like RxNorm and SNOMED.

VOCABULARY	ID	CODE	NAME	CLASS	RC	DRC	DOMAIN	VOCABULARY
NDC (6889)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
RxNorm (2096)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic]	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
SPL (1677)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic] Box of 20	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
RxNorm Extension (1094)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic] Box of 30	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
SNOMED (761)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic] Box of 30 by SANOFI AVENTIS FRANCE	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
NDFRT (83)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic] Box of 30	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
HCPCS (17)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic] Box of 30	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension
LOINC (4)	43143682	OMOP432277	1020 MG Aspirin 0.489 MG/MG Powder for Oral Solution [Aspegic] Box of 30	Quant Clinical Drug	timeout	timeout	Drug	RxNorm Extension



- Used extensively during concept mapping process



2018 OHDSI PoC results

PoC completed in record times by mid-September, 2018

- OMOP CDM version 5.3 populated with Danish colorectal cancer data
- ~2,000 custom concepts created and mapped
- 13,500 total concepts mapped
- ATLAS 2.5.2 installed (upgraded to 2.7.3 in June 2019)
- Enabled ARACHNE Execution Engine to run PLE/PLP studies

Done!!!

Nope, it is just a beginning



Interesting Challenge #1

“Computed” Custom Concepts

To address research needs, we created a number of custom concepts that were computed.

“Neutrophil-to-Lymphocyte Ratio” = ratio of “Neutrophils” and “Lymphocytes”

Used for cohort creation as well as a covariate in PLP. Such concepts may be subject to further proposal for adding them into official vocabularies (like LOINC).

Opportunity (pros and cons):

Should it be an enhancement enhancement in ATLAS?

Or

should these be precomputed during the ETL CDM?



Interesting Challenge #2

Storing “Negative information” e.g. absence of off

“No diabetes mellitus”

Introduced a new approach storing all negative information in OBSERVATION table by mapping the source entities to ‘No evidence of’ (Maps to) and the entity itself (Maps to value, can be disorder, procedure, observation or any other domain).



Interesting Challenge #3

Storing rich Oncology data

Oncology data is complicated and sometimes obscure. The granularity of our datasets didn't allow us to map it to the existing concepts without losing important aspects of disorders.

neurofibrosarcoma, relapse

malignant schwannoma, direct spread

malignant schwannoma, uncertain whether primary or metastatic

precursor B-lymphoblastic lymphoma / leukemia relapse [<1.1.04]

T-cell chronic lymphocytic leukemia, relapsed

Hodgkin lymphoma in incomplete remission

How to store cancer stages??

Opportunity:

OMOP CDM Oncology Extension

Richer oncology vocabularies



PoC Learnings

- Strict QA/QC and validation is a must
- Vocabulary mappings “done right” is critical. Agree on “mapping review and validation” process. And yes - there are sometimes errors and gaps in OHDSI Vocabularies too!
- Sometimes there is no “black and white” in mapping a concept. ~11% were wrong, ~35% with less granularity
- OHDSI components must be harmonized and up to date – it’s about a full stack e.g. OMOP CDM, ATLAS, Method Packages, latest vocabularies, R libraries /R
- Disciplined delivery approach and ongoing communication

Vocabulary Mappings Process - Region of Zealand



• Only non-standard mappings should be adjusted

** Modifications to standardized OHDSI mappings should be routed to OHDSI community for review. Odysseus will flag such instances and discussion will take place on next steps for each case



Hackathons



7 sources: 1) colorectal cancer, 2) anesthesia, 3) pathology, 4) microbiology, 5) causes of death, 6) biochemistry, 7) in-hospital medication



13,683 concepts (54,761 patients)



4 months (March – June 2019)



12 Medical doctors + 2 Data scientists in two teams:

- A great team of 12 MDs sweeping through the mapping files
- A task-force of 6 MD with more experience in medicine and OMOP, finetuning and approving the corrections



46% improvements in mapping quality identified:

- 11% concepts mapped completely wrong
- 35% concepts mapped with granularity loss



73% of the erroneous mappings corrected

- 76% of the wrong mappings corrected
- 72% of the granularity loss retrieved




Hackathons



56	Source	Maps to	Target
Vocabulary	DCCG		SNOMED
Variable (code)	Anastomose_teknik 1		
ID	2000047024		<u>4120001</u>
Text.dk	en anvendte anastomoseteknik (håndsyet-staplet-anden)		
Text.en	Anastomosis technique: hand-stitched		Internal fixation using staple
	Tag 1		Tag 2
Choice	Wrong		Wrong
Comment	Håndsyet anastomose, ikke stapler		
New Choice	Wrong ▾		Wrong ▾
New Comment	Håndsyet anastomose, ikke stapler		
	Solution		Status
Coice	Map to new concept		Approved
New ID	4191857		
New Concept			
Comment	replace		new tag
New Choice	Map to new concept ▾		Approved ▾
New New ID	4191857		
New N. Concept	Multi-layer hand sewn intestinal anastomosis		
New Comment	replace		new tag

Hackathons

50	Source	Maps to	Target
Vocabulary	DCCG		SNOMED
Variable (code)	Anastomose_orientering 4		
ID	2000046444		<u>4078639</u>
Text.dk	Angivelse af anastomosens orientering		
Text.en	Anastomosis orientation: page-to-page		Type of anastomosis
	Tag 1		Tag 2
Choice	OK		OK
Comment	Engelsk oversættelse forkert (page)		
New Choice	OK ▾		OK ▾
New Comment	Engelsk oversættelse forkert (page)		
	Solution		Status
Coice	Not needed		Approved
New ID			
New Concept			
Comment			
New Choice	Not needed ▾		Approved ▾
New New ID			
New N. Concept			
New Comment			





Patient X

- Gender: Female
- Age: 64
- Colon tumour
- Stage 2
- Is having a primary malignant neoplasm of unknown site.
Colon tumour may be considered secondary condition.



Patient X

- Gender: Female
- Age: 64
- Colon tumour
- Stage 2
- Experiencing discomfort and weight loss because (cachexia) of cancer



A network of excellence for Personalized Oncological Surgery



AIM

A network for excellence aiming to establish a research platform for **personalized medicine in surgery** through a collaboration between scientist and stakeholders in the clinical pathway of the surgical oncological patient in order to **reduce morbidity and increase cancer survival.**



One-week workshop in Personalized Oncological Surgery



June 2019



Kusadasi,
Turkey



27

medical professionals

+



7

data scientists

+



7

days

=

EDUCATION - INFRASTRUCTURE - RESEARCH



Study design &
cohort definition
using ATLAS



Standardized population
level estimations &
patient level predictions



Validation of the PM
infrastructure of
CAG-POS



Clinical questions &
hypotheses validation
in real-time



4 + 1
research papers



Penelopes, Ulysses' and Hommers



- Adile Orhan, Center for Surgical Science
- Anna Ostropolets, Columbia University
- Alexander Davydov, Odysseus
- Andreas Rosen, Center for Surgical Science
- Betul Okutan, Center for Surgical Science
- Camilla Grube, Center for Surgical Science
- Dunja Kokotovic, Center for Surgical Science
- Eldar Allakhverdijev, Odysseus
- Ellen Bjerrum, Center for Surgical Science
- Emma Hølmich, Center for Surgical Science
- Fatima Buzquurz, Center for Surgical Science
- Greg Klebanov, Odysseus
- Hans Raskov, Center for Surgical Science
- Iannis Drakos, Center for Surgical Science
- Ilya Pyatin, Odysseus
- Ismail Gögenur, Center for Surgical Science
- Johanne Gormsen, Center for Surgical Science
- Kirsten Wahlstrøm, Center for Surgical Science
- Luyi Cai, Center for Surgical Science
- Mahdi Alamili, Center for Surgical Science
- Maria Pozhidaeva, Odysseus
- Morten Hartwig, Center for Surgical Science
- Nicolas Dérian, Center for Surgical Science
- Patrick Ryan, OHDSI
- Pavel Grafkin, Odysseus
- Peter Rijnbeek, OHDSI
- Puk Kristiansen, Center for Surgical Science
- Rasmus Bojesen, Center for Surgical Science
- Rasmus Vogelsang, Center for Surgical Science
- Rune Hasselager, Center for Surgical Science
- Rune Trangbæk, Center for Surgical Science
- Sofie Møller, Center for Surgical Science
- Thea Degett, Center for Surgical Science
- Tina Fransgård, Center for Surgical Science
- Ali Shaker, Center for Surgical Science
- Jawad Ahmad Zahid, Center for Surgical Science



Study 1

Exposure to inhalation anesthesia and risk of mortality for patients undergoing surgery for colorectal cancer

Rune Petring Hasselager, MD¹, Andreas Weinberger Rosen, MD¹, Tina Fransgaard, MD, PhD¹, Mahdi Alamili, MD, PhD¹, Johanne Gormsen, BSc¹, Thea Helene Degett, MD, PhD¹, Nicolas Derian, PhD¹, Pavel Grafkin, MSc⁶, Peter Rijnbeek, PhD², Patrick Ryan, PhD^{3,4,5}, Ismail Gögenur, MD, DMSc¹, Iannis Drakos, PhD¹

¹Center for Surgical Science, Zealand University Hospital, Denmark,

²Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands,

³Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA,

⁴Department of Biomedical Informatics, Columbia University, New York, New York, USA,

⁵Janssen Pharmaceuticals, New Jersey, USA

⁶Odysseus Data Services Inc., Cambridge, Massachusetts, USA





Study 2



Prediction of 90-day mortality after colorectal cancer surgery through standardized perioperative data analysis

Rasmus Vogelsang MD¹, Rasmus Bojesen MD¹, Emma Hoelmich BMSc¹, Adile Orhan BMSc¹, Fatima Buzquurx BMSc¹, Luyi Cai BMSc¹, Camilla Grube BMSc¹, Jawad Zahid BMSc¹, Hans Raskov MD¹, Gregory Klebanov, MSc⁶, Iannis Drakos PhD¹, Nicolas Derian PhD¹, Patrick Ryan PhD^{3,4,5}, Peter Rijnbeek PhD², Ismail Gögenur MD, DMSc¹

¹Center for Surgical Science, Zealand University Hospital, Denmark,

²Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands,

³Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA,

⁴Department of Biomedical Informatics, Columbia University, New York, New York, USA,

⁵Janssen Pharmaceuticals, New Jersey, USA

⁶Odysseus Data Services Inc., Cambridge, Massachusetts, USA





Study 3



Data driven hypothesis generation using the OMOP Common Data Model

Andreas Rosen¹, Nicholas Derian, PhD¹, Anna Ostropolets, MSc⁶, Peter Rijnbeek, PhD², Patrick Ryan, PhD^{3,4,5}, Ismail Gögenur, MD, DMSc¹, Iannis Drakos, PhD¹ & the Center for Surgical Science Consortium¹

¹Center for Surgical Science, Zealand University Hospital, Denmark,

²Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands,

³Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA,

⁴Department of Biomedical Informatics, Columbia University, New York, New York, USA,

⁵Janssen Pharmaceuticals, New Jersey, USA

⁶Odysseus Data Services Inc., Cambridge, Massachusetts, USA





Study 4



Characterization of anemic and non-anemic colorectal cancer patients undergoing cancer surgery

Ali Abbas Shaker, MD¹, Rune Petring Hasselager, MD¹, Andreas Weinberger Rosen, MD¹, Tina Fransgaard, MD, PhD¹, Mahdi Alamili, MD, PhD¹, Johanne Gormsen, BSc¹, Thea Helene Degett, MD, PhD¹, Eldar Allakhverdiiev, MSc⁶, Iannis Drakos, PhD¹, Peter Rijnbeek, PhD², Patrick Ryan, PhD^{3,4,5}, Ismail Gögenur, MD, DMSc¹, Nicolas Derian, PhD¹

¹Center for Surgical Science, Zealand University Hospital, Denmark,

²Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands,

³Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA,

⁴Department of Biomedical Informatics, Columbia University, New York, New York, USA,


⁵Janssen Pharmaceuticals, New Jersey, USA

⁶Odysseus Data Services Inc., Cambridge, Massachusetts, USA






The patient pathway





Critical phases of the patient journey





The best OHDSI slide ever!





Loosing a bet on the OHDSI journey!





The many faces of mapping!





The pleasures on the OHDSI journey!



Personalized Oncological Surgery
The right treatment to the right patient
at the right time

Thank you for your attention!



Presented by Prof. Ismail Gögenur, DMSc
Director of the Center for Surgical Science (CSS)